187 related articles for article (PubMed ID: 15585918)
41. Idiotypic vaccination in B-cell malignancies.
Bianchi A; Massaia M
Mol Med Today; 1997 Oct; 3(10):435-41. PubMed ID: 9358470
[TBL] [Abstract][Full Text] [Related]
42. Recent advances in multiple myeloma immunotherapy.
Ruffini PA; Biragyn A; Kwak LW
Biomed Pharmacother; 2002 May; 56(3):129-32. PubMed ID: 12046683
[TBL] [Abstract][Full Text] [Related]
43. Vaccination with dendritic cell-tumor fusion cells in multiple myeloma patients: a promising strategy?
Garcia-Marquez MA; Shimabukuro-Vornhagen A; Theurich S; von Bergwelt-Baildon M
Immunotherapy; 2013 Oct; 5(10):1039-42. PubMed ID: 24088074
[TBL] [Abstract][Full Text] [Related]
44. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.
Rosenblatt J; Vasir B; Uhl L; Blotta S; Macnamara C; Somaiya P; Wu Z; Joyce R; Levine JD; Dombagoda D; Yuan YE; Francoeur K; Fitzgerald D; Richardson P; Weller E; Anderson K; Kufe D; Munshi N; Avigan D
Blood; 2011 Jan; 117(2):393-402. PubMed ID: 21030562
[TBL] [Abstract][Full Text] [Related]
45. Novel immunotherapies.
Yi Q
Cancer J; 2009; 15(6):502-10. PubMed ID: 20010170
[TBL] [Abstract][Full Text] [Related]
46. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells.
Märten A; Renoth S; von Lilienfeld-Toal M; Buttgereit P; Schakowski F; Glasmacher A; Sauerbruch T; Schmidt-Wolf IG
Haematologica; 2001 Oct; 86(10):1029-37. PubMed ID: 11602408
[TBL] [Abstract][Full Text] [Related]
47. The role of idiotype vaccines in the treatment of human B-cell malignancies.
Bendandi M
Expert Rev Vaccines; 2004 Apr; 3(2):163-70. PubMed ID: 15056042
[TBL] [Abstract][Full Text] [Related]
48. [In vitro anti-myeloma effects induced by myeloma idiotype-protein pulsed dendritic cell vaccine].
Zhang M; Yin XR; Luo YY; Lin X; Wang MC; He PC; Li J; Guo GL; Cai RH; Liu YL
Zhonghua Xue Ye Xue Za Zhi; 2005 Oct; 26(10):593-7. PubMed ID: 16532967
[TBL] [Abstract][Full Text] [Related]
49. [Dendritic cell-based immunotherapy for multiple myeloma -- review].
Zhu XJ; He L; Sun XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):821-5. PubMed ID: 19549416
[TBL] [Abstract][Full Text] [Related]
50. Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.
Danylesko I; Beider K; Shimoni A; Nagler A
Clin Dev Immunol; 2012; 2012():753407. PubMed ID: 22649466
[TBL] [Abstract][Full Text] [Related]
51. Immune therapies.
Prabhala RH; Munshi NC
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1217-30, x-xi. PubMed ID: 17996595
[TBL] [Abstract][Full Text] [Related]
52. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor.
Kwak LW; Taub DD; Duffey PL; Bensinger WI; Bryant EM; Reynolds CW; Longo DL
Lancet; 1995 Apr; 345(8956):1016-20. PubMed ID: 7723498
[TBL] [Abstract][Full Text] [Related]
53. Active immunotherapy of multiple myeloma.
Houet L; Veelken H
Eur J Cancer; 2006 Jul; 42(11):1653-60. PubMed ID: 16797966
[TBL] [Abstract][Full Text] [Related]
54. Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma.
Reichardt VL; Okada CY; Stockerl-Goldstein KE; Bogen B; Levy R
Biol Blood Marrow Transplant; 1997 Aug; 3(3):157-63. PubMed ID: 9310193
[TBL] [Abstract][Full Text] [Related]
55. Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.
Dembic Z; Schenck K; Bogen B
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2697-702. PubMed ID: 10706628
[TBL] [Abstract][Full Text] [Related]
56. Dendritic cells: potential role in cancer therapy.
Engleman EG
Cytotechnology; 1997; 25(1-3):1-8. PubMed ID: 9474803
[TBL] [Abstract][Full Text] [Related]
57. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma.
Cull G; Durrant L; Stainer C; Haynes A; Russell N
Br J Haematol; 1999 Dec; 107(3):648-55. PubMed ID: 10583271
[TBL] [Abstract][Full Text] [Related]
58. Idiotype-specific CD4(+) T cells eradicate disseminated myeloma.
Haabeth OA; Tveita A; Fauskanger M; Hennig K; Hofgaard PO; Bogen B
Leukemia; 2016 May; 30(5):1216-20. PubMed ID: 26449664
[No Abstract] [Full Text] [Related]
59. Therapeutic idiotype vaccines in B lymphoproliferative diseases.
Coscia M; Kwak LW
Expert Opin Biol Ther; 2004 Jun; 4(6):959-63. PubMed ID: 15174977
[TBL] [Abstract][Full Text] [Related]
60. Active idiotype vaccination in multiple myeloma. GM-CSF may be an important adjuvant cytokine.
Mellstedt H; Osterborg A
Pathol Biol (Paris); 1999 Feb; 47(2):211-5. PubMed ID: 10192891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
